IPSEN (OTCMKTS:IPSEY) Share Price Passes Above 200-Day Moving Average - Time to Sell?

Key Points

• IPSEN's share price has recently surpassed its 200-day moving average of $29.72, reaching a high of $34.09 during trading.
• The company announced an increase in its dividend, with investors receiving a payment of $0.2896 per share, a significant rise from the previous dividend of $0.23.
• IPSEN operates as a biopharmaceutical company focusing on oncology, neuroscience, and rare diseases, with multiple products in varying stages of clinical trials.

Shares of IPSEN (OTCMKTS:IPSEY - ) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $29.72 and traded as high as $34.09. IPSEN shares last traded at $34.09, with a volume of 2,170 shares trading hands.

IPSEN Stock Up 1.0%

The business has a 50 day moving average of $31.05 and a 200-day moving average of $29.72.

IPSEN Increases Dividend

The business also recently announced a dividend, which was paid on Wednesday, June 25th. Investors of record on Tuesday, June 10th were paid a $0.2896 dividend. This represents a yield of 97.0%. The ex-dividend date of this dividend was Monday, June 9th. This is an increase from IPSEN's previous dividend of $0.23.

About IPSEN

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.